Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aminopromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.68 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.68 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.68 |
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.68 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.68 |
| ▸ | KCNH2 known ✓ | Q12809 | 6/20 | 0.68 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.68 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.68 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.68 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.68 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.68 |
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 0.63 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.63 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.63 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.63 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.63 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.63 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminopromazine SCHEMBL30990818 | 0.98 | CHRM2 (0.70) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Aminopromazine SCHEMBL25156 | 0.98 | CHRM2 (0.70) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Aminopromazine SCHEMBL11041925 | 0.87 | GFER (0.59) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Aminopromazine SCHEMBL11041921 | 0.87 | GFER (0.59) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Hydrochloric Acid SCHEMBL8050972 | 0.85 | LMNA (0.66) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Methylpromazine SCHEMBL2774391 | 0.83 | CHRM2 (0.97) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| SCHEMBL3475700 | 0.83 | CYP2D6 (0.65) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Hydrochloric Acid SCHEMBL28702086 | 0.82 | HTR1A (0.68) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Methylpromazine SCHEMBL29354434 | 0.81 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Methylpromazine SCHEMBL18993 | 0.81 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| WO-2007041677-A9 | SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF | COMBINATORX INC (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007041593-A2 | ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041584-A2 | IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041463-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041677-A2 | SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| US-4833138-A | Phenothiazinealkaneamines for treatment of neurotoxic injury | WASHINGTON UNIVERSITY (US) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | CHRM2 1603/4885HTR1A 3411/4885CHRM1 2602/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | CHRM2 3247/4885HTR1A 2037/4885CHRM1 3915/4885 |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | COL2A1, MMP1, FN1 | CHRM2 1832/4885HTR1A 2387/4885CHRM1 3219/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | CHRM2 1603/4885HTR1A 3411/4885CHRM1 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.